Summary of Study ST001515
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001022. The data can be accessed directly via it's Project DOI: 10.21228/M8KT26 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001515 |
Study Title | A Metabolomic Signature of Glucagon Action in Healthy Individuals with Overweight/Obesity Humans |
Study Summary | Objective: We sought to identify the circulating metabolites that would serve as markers of glucagon action. Design: In this study, we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity. Participants were randomized to either glucagon (12.5 ng/kg/min) (GCG 12.5) or glucagon (25 ng/kg/min) GCG 25 or a placebo control were included. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity. |
Institute | Translational Research Institute- AdventHealth Orlando |
Last Name | Whytock |
First Name | Katie |
Address | 301 E Princeton St, Orlando, FL, 32804 |
Katie.Whytock@adventhealth.com | |
Phone | 321-945-9982 |
Submit Date | 2020-10-26 |
Num Groups | 3 |
Total Subjects | 33 |
Raw Data Available | Yes |
Analysis Type Detail | LC-MS |
Release Date | 2020-12-01 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001604 |
Treatment Summary: | Study subjects were admitted to the Clinical Research Unit (CRU) at the Translational Research Institute (TRI) at AdventHealth for 5 overnight stays. The first 2 overnight stays were used as baseline. On the 2nd day (Day -1), a baseline blood draw (-24 hours) was performed. On Day 1, a blood draw was again taken approximately 30 minutes prior to the start of the glucagon infusion. The study subjects began a ramped infusion (first 4 hours) of either saline (Placebo), Low Dose Glucagon (12.5ng/kg/min) or High Dose Glucagon (25ng/kg/min) for the next 72 hours (Inpatient). The Glucagon (GlucaGen, Novo Nordisk, Bagsværd Denmark) was administered under an FDA-approved IND (#136634). Intravenous (IV) bags of the study medication were hung together on an IV pole and changed out every 24 hours to provide a continuous infusion. With the exception of the 4-hour time point, all draws were performed in the overnight fasted state. |